List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers recently conducted a genome-wide association study (GWAS) to identify factors that increase susceptibility to the incurable lung condition idiopathic pulmonary fibrosis (IPF). Here, Dr Richard Allen shares some of the study’s key findings.
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
4 June 2020 | By Biosensing Instrument
In this webinar, we will provide an overview of the technology with some application examples and also see a case study how AstraZeneca is exploring SPRM for studies on G-protein-coupled receptors (GPCR) in close collaboration with Biosensing Instrument.
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
Administering a novel complement protein blocker (B4Crry) alongside reperfusion therapy improved cognitive and motor recovery in a model of ischemic stroke.
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).
Researchers found there is a gradient of SARS-CoV-2 infectivity down the airway and that the severe pneumonia symptoms may be caused by aspiration of oral contents into the lungs.
